In the first six months of 2023, Podravka Group achieved sales revenues of 346.3 million euros, which is 25.6 million euros, or eight percent higher compared to the same period last year. Revenues from the Food segment amounted to 265.2 million euros, an increase of 11.2 million or 4.4 percent compared to the first half of 2022. The Pharmaceuticals segment recorded a significant growth of 21.6 percent, or 14.4 million euros, achieving 81 million euros in revenue.
The Group’s operating profit before depreciation (EBITDA) reached 48.3 million euros in the first six months of this year, 0.1 million euros less than in the same period last year.
However, the contribution of Food to the Group’s EBITDA is lower than last year as the food business continues to be strongly affected by the costs of raw materials, packaging, and energy. Specifically, in the Food segment, their costs increased by 9.3 million euros, which is 8.3 percent higher than in the same period last year. Significant attention is therefore still focused on controlling all costs, along with mitigating them by optimizing the production assortment, managing production processes, and making changes in procurement processes.
The net profit of Podravka Group amounted to 45.2 million euros. Compared to the first six months of 2022, this represents an increase of 18.9 million euros. However, this growth is under the one-time impact of tax incentives amounting to 19.7 million euros, which were granted to Podravka by the Ministry of Economy and Sustainable Development based on the Investment Promotion Act. Podravka received the status of a support beneficiary based on investments in capacity expansion and increasing business competitiveness through the construction of a new LDC and equipping factories in Koprivnica and Varaždin.
The total tax incentive must be reported in the first year of using the tax incentive. When excluding the effects of its application, the normalized net profit of the Group in the first six months amounted to 26 million euros, which is 0.4 percent higher compared to the same period in 2022. The normalized net profit of Pharmaceuticals increased by 65 percent and amounted to 13 million euros, the same as Food, which still shows a significant negative impact from rising raw material costs, resulting in a profit decline of 27.9 percent.
– I am satisfied with the results in the first half of the year, despite the fact that the Group’s operations are still exposed to strong price increases in energy, raw materials, and packaging, especially in Food. Despite some calming of market turbulence and actively seeking the most favorable conditions, the realized prices are still significantly higher than those we paid in 2022. I am also pleased with the advances in sales in our foreign markets, especially the first results of cooperation with Atlantic Group, as well as the results of restructuring sales in the Polish and German markets, which will enable greater sales profitability in Poland, as well as greater presence and profitability in the German market.
